Gonadal Damage in Hodgkin’s Disease from Cancer Chemotherapeutic Regimens
- 1 January 1984
- book chapter
- Published by Springer Nature
- Vol. 7, 140-145
- https://doi.org/10.1007/978-3-642-69132-4_16
Abstract
The paper re-emphasizes that intesive prolonged anticancer chemotherapy containing alkylating agents or procarbazine or both produces a high-incidence of gonadal failure, particularly in males. This evidence has been documented mostly in patients with Hodgkin’s disease. On the contrary, effective combination regimens, such as ABVD, not including the above mentioned drugs induce a comparatively less and transient germ cell toxicity. In devising chemotherapy for potentially curable neoplastic diseases in young patients efforts should be made to avoid or minimize the potential risk of drug-induced gonadal failure.Keywords
This publication has 12 references indexed in Scilit:
- Drug selection in the treatment of Hodgkin's diseaseHematological Oncology, 1983
- Gonadal function in Hodgkin's disease: long-term follow-up of chemotherapy.BMJ, 1982
- Testicular dysfunction in untreated Hodgkin's diseaseThe American Journal of Medicine, 1982
- Long-term follow-up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's diseaseThe American Journal of Medicine, 1981
- Female Reproductive Potential after Treatment for Hodgkin's DiseaseNew England Journal of Medicine, 1981
- PROTECTION FROM CYCLOPHOSPHAMIDE-INDUCED TESTICULAR DAMAGE WITH AN ANALOGUE OF GONADOTROPIN-RELEASING HORMONEThe Lancet, 1981
- The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky memorial lectureCancer, 1981
- Cytotoxic-induced ovarian failure in women with Hodgkin's disease. I. Hormone functionJAMA, 1979
- CYCLICAL COMBINATION CHEMOTHERAPY AND GONADAL FUNCTIONThe Lancet, 1979
- Effect of Drug Treatment for Lymphoma on Male Reproductive CapacityAnnals of Internal Medicine, 1973